Totaligent, Inc. 8-K

What Happened Totaligent, Inc. announced on March 22, 2026 that it entered into an Extension Amendment to the Binding Letter of Intent (LOI) with GloMed Solutions LLC. The original LOI (dated February 22, 2026) contemplates forming a joint venture and grants Totaligent a call option to acquire GloMed, including its operations, intellectual property, and related assets. The Amendment extends the target dates for negotiating and executing definitive transaction documents and the target closing date to April 22, 2026.

Key Details

• Amendment executed: March 22, 2026; original LOI dated February 22, 2026.
• New target date for negotiation/execution and target closing: April 22, 2026.
• Exclusivity period from the LOI is extended through April 22, 2026 (or earlier as provided in the LOI).
• Definitive agreements contemplated include joint venture agreements, asset contribution agreements, and intellectual property assignment agreements; the Amendment is filed as Exhibit 10.1.

Why It Matters The extension gives Totaligent and GloMed additional time for negotiations and due diligence on a proposed joint venture and potential acquisition. For investors, this means the timeline for any definitive deal or change in Totaligent’s business or asset base has been pushed to mid‑April 2026, but the LOI’s exclusivity remains in effect—limiting other parties from negotiating during the extended period. The filing does not change the substantive terms of the LOI except for the timing.